[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1113378T1 - Καινοτομος χρηση των αντισωματων αντι il-1bhta - Google Patents

Καινοτομος χρηση των αντισωματων αντι il-1bhta

Info

Publication number
CY1113378T1
CY1113378T1 CY20121100867T CY121100867T CY1113378T1 CY 1113378 T1 CY1113378 T1 CY 1113378T1 CY 20121100867 T CY20121100867 T CY 20121100867T CY 121100867 T CY121100867 T CY 121100867T CY 1113378 T1 CY1113378 T1 CY 1113378T1
Authority
CY
Cyprus
Prior art keywords
compounds
rheumatoid arthritis
receptor
antibodies
disrupt
Prior art date
Application number
CY20121100867T
Other languages
English (en)
Inventor
Phil Lowe
Hermann Gram
Thomas Jung
Timothy Wright
Trevor Mundel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113378(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1113378T1 publication Critical patent/CY1113378T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Η παρούσα περιγραφή αναφέρεται στη χρήση ενώσεων που διακόπτουν τη σύνδεση του συνδέτη IL-1β με τον IL-1 υποδοχέα (στο παρόν αναφερόμενες ως «Ενώσεις IL-1 βήτα»), όπως είναι μικρές μοριακές ενώσεις που διακόπτουν την αλληλεπίδραση του συνδέτη IL-1β με τον υποδοχέα IL-1, αντισώματα έναντι της IL-1β ή αντισώματα έναντι των υποδοχέων IL-1, π.χ. μόρια που προσδένουν την IL-1 β που περιγράφηκαν στο παρόν, π.χ. ενώσεις που προσδένουν την IL-1β ή τους υποδοχείς της IL-1, και/ή RNA ενώσεις που ελαττώνουν είτε τους συνδέτες IL-1β ή τα επίπεδα των πρωτεϊνικών υποδοχέων της IL-1, για την αντιμετώπιση και/ή τη πρόληψη των αυτό-φλεγμονωδών συνδρόμων, π.χ. της νεανικής ρευματοειδούς αρθρίτιδας ή του συνδρόμου ρευματοειδούς αρθρίτιδας των ενηλίκων και σε μεθόδους αντιμετώπισης και/ή πρόληψης των αυτό-φλεγμονωδών συνδρόμων, π.χ. της νεανικής ρευματοειδούς αρθρίτιδας ή του συνδρόμου της ρευματοειδούς αρθρίτιδας των ενηλίκων, στα θηλαστικά, συγκεκριμένα στους ανθρώπους.
CY20121100867T 2005-10-26 2012-09-24 Καινοτομος χρηση των αντισωματων αντι il-1bhta CY1113378T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73043505P 2005-10-26 2005-10-26
US74212505P 2005-12-02 2005-12-02
EP06826560A EP1940465B1 (en) 2005-10-26 2006-10-24 Novel use of anti il-1beta antibodies

Publications (1)

Publication Number Publication Date
CY1113378T1 true CY1113378T1 (el) 2015-11-04

Family

ID=37806690

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20121100867T CY1113378T1 (el) 2005-10-26 2012-09-24 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY2013046C CY2013046I1 (el) 2005-10-26 2013-12-13 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY20181100301T CY1120018T1 (el) 2005-10-26 2018-03-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
CY2018018C CY2018018I2 (el) 2005-10-26 2018-06-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα

Family Applications After (3)

Application Number Title Priority Date Filing Date
CY2013046C CY2013046I1 (el) 2005-10-26 2013-12-13 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY20181100301T CY1120018T1 (el) 2005-10-26 2018-03-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
CY2018018C CY2018018I2 (el) 2005-10-26 2018-06-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα

Country Status (29)

Country Link
US (8) US8105587B2 (el)
EP (5) EP3332807B1 (el)
JP (4) JP2009513645A (el)
KR (3) KR20170038131A (el)
CN (2) CN101291693B (el)
AU (1) AU2006306280B2 (el)
BR (1) BRPI0617830B8 (el)
CA (3) CA2898369C (el)
CY (4) CY1113378T1 (el)
DK (2) DK1940465T3 (el)
ES (3) ES2944067T3 (el)
HK (3) HK1121041A1 (el)
HU (2) HUE036973T2 (el)
IL (4) IL190545A (el)
JO (2) JO2826B1 (el)
LT (3) LT2848258T (el)
LU (2) LU92326I2 (el)
MA (1) MA29919B1 (el)
NO (2) NO345888B1 (el)
NZ (1) NZ567222A (el)
PH (2) PH12013501287B1 (el)
PL (2) PL1940465T3 (el)
PT (2) PT1940465E (el)
RU (2) RU2468817C2 (el)
SI (2) SI1940465T1 (el)
TN (1) TNSN08189A1 (el)
TR (1) TR201802449T4 (el)
TW (3) TWI388335B (el)
WO (1) WO2007050607A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1940465T1 (sl) 2005-10-26 2012-10-30 Novartis Ag Nova uporaba protiteles proti IL-1 beta
MX2009012948A (es) * 2007-05-29 2009-12-14 Novartis Ag Nuevas indicaciones para la terapia anti-il-1-beta.
AU2012203932B2 (en) * 2007-05-29 2014-04-24 Novartis Ag New indications for anti-IL-I-beta therapy
US20110189172A1 (en) * 2008-06-06 2011-08-04 Xoma Technology, Ltd. Methods for the treatment of rheumatoid arthritis
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
BR112012007365A2 (pt) * 2009-10-15 2016-11-22 Abbott Lab proteínas de ligação à il-1
PL2571532T3 (pl) * 2010-05-14 2017-10-31 Abbvie Inc Białka wiążące IL-1
KR20130133247A (ko) * 2010-12-21 2013-12-06 애브비 인코포레이티드 Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
SG194710A1 (en) 2011-05-10 2013-12-30 Nestec Sa Methods of disease activity profiling for personalized therapy management
WO2017153936A1 (en) 2016-03-10 2017-09-14 Novartis Ag Chemically modified messenger rna's
CN111094984A (zh) 2017-05-31 2020-05-01 普罗米修斯生物科学公司 克罗恩氏病患者的粘膜愈合评估方法
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
BR112020022576A2 (pt) * 2018-05-09 2021-02-09 Novartis Ag uso de canaquinumabe
SG11202104699TA (en) * 2018-12-21 2021-07-29 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
US20220056123A1 (en) 2018-12-21 2022-02-24 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
WO2023132698A1 (ko) * 2022-01-10 2023-07-13 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5350683A (en) * 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
AU1513495A (en) 1993-12-14 1995-07-03 University Of Pittsburgh Systemic gene treatment of connective tissue diseases
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
AU778975B2 (en) 1999-02-10 2004-12-23 Interleukin Genetics, Inc. Therapeutics and diagnostics based on an IL-1B mutation
CZ200283A3 (cs) * 1999-07-16 2002-06-12 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemis Aminobenzofenony jako inhibitory IL-1beta a TNF-alfa
ES2219388T3 (es) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
AU2001259758A1 (en) * 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
NZ525656A (en) 2000-11-07 2004-12-24 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
EP1423432A4 (en) * 2001-07-26 2006-01-11 Lilly Co Eli ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
MXPA04001187A (es) * 2001-08-07 2004-07-08 Immunex Corp Receptores de interleucina-1 en el tratamiento de enfermedades.
AU2002365713A1 (en) 2001-12-01 2003-06-17 John Charles Balson Ac synchronous generator incorporating a braking mechansim
KR200268109Y1 (ko) 2001-12-06 2002-03-15 김정훈 편평형 무정류자 진동모터
EA011488B1 (ru) 2002-02-01 2009-04-28 Ариад Джин Терапьютикс, Инк. Фосфорсодержащие соединения и их получение
MXPA04007124A (es) 2002-02-01 2004-10-29 Omeros Corp Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
KR20040105710A (ko) * 2002-02-11 2004-12-16 아르키온 라이프 사이언씨즈 엘엘씨 정제된 사이토킨 억제인자
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
KR20050084224A (ko) 2002-12-09 2005-08-26 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 야누스 티로신 키나제 3을 선택적으로 저해하는 방법
ES2567198T3 (es) 2003-01-24 2016-04-20 Applied Molecular Evolution, Inc. Antagonistas de la IL-1 beta humana
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
CA2545733A1 (en) 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
MXPA06007640A (es) 2004-01-12 2007-04-17 Cytopia Res Pty Ltd Inhibidores de quinasa selectivos.
AU2005216298B2 (en) * 2004-02-26 2010-09-02 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
CA2567080A1 (en) * 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
US7459426B2 (en) * 2004-06-04 2008-12-02 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat autoinflammatory disease
JP2009501128A (ja) 2005-01-20 2009-01-15 ユニバーシティー オブ ロチェスター 炎症疾患および炎症障害の研究および処置のための組成物および方法
EP2371967B1 (en) 2005-03-18 2015-06-03 DSM IP Assets B.V. Production of carotenoids in oleaginous yeast and fungi
KR101502920B1 (ko) 2005-06-21 2015-03-17 조마 (유에스) 엘엘씨 ＩＬ-１β 결합성 항체 및 그의 단편
SI1940465T1 (sl) 2005-10-26 2012-10-30 Novartis Ag Nova uporaba protiteles proti IL-1 beta

Also Published As

Publication number Publication date
US20130171167A1 (en) 2013-07-04
DK2848258T3 (en) 2018-03-19
EP1940465B1 (en) 2012-08-01
LTPA2018506I1 (lt) 2018-06-25
JP2016020377A (ja) 2016-02-04
US20080286266A1 (en) 2008-11-20
JP6286403B2 (ja) 2018-02-28
JP6061747B2 (ja) 2017-01-18
TWI388335B (zh) 2013-03-11
AU2006306280A1 (en) 2007-05-03
KR101518064B1 (ko) 2015-05-06
TNSN08189A1 (en) 2009-10-30
CY2018018I1 (el) 2018-12-12
BRPI0617830A2 (pt) 2011-08-09
CN102861332A (zh) 2013-01-09
PL1940465T3 (pl) 2013-01-31
US20180201674A1 (en) 2018-07-19
US20170218063A1 (en) 2017-08-03
LTC2848258I2 (lt) 2019-08-12
IL190545A0 (en) 2008-11-03
NO345888B1 (no) 2021-09-27
US20120039910A1 (en) 2012-02-16
BRPI0617830B1 (pt) 2020-10-20
IL258983A (en) 2018-06-28
LU92326I2 (fr) 2014-02-05
US8105587B2 (en) 2012-01-31
CY1120018T1 (el) 2018-12-12
WO2007050607A2 (en) 2007-05-03
EP2848258A1 (en) 2015-03-18
US20150322148A1 (en) 2015-11-12
RU2571563C2 (ru) 2015-12-20
CA2898369A1 (en) 2007-05-03
LU92326I9 (el) 2019-01-16
TWI626056B (zh) 2018-06-11
SI2848258T1 (en) 2018-03-30
US20210147533A1 (en) 2021-05-20
PT1940465E (pt) 2012-10-03
RU2468817C2 (ru) 2012-12-10
EP4218815A2 (en) 2023-08-02
KR101749388B1 (ko) 2017-06-20
NO20082344L (no) 2008-07-22
JP2017206552A (ja) 2017-11-24
EP4218815A3 (en) 2024-03-27
CY2013046I2 (el) 2015-11-04
TW201617097A (zh) 2016-05-16
WO2007050607A3 (en) 2007-06-28
HK1252316A1 (zh) 2019-05-24
TR201802449T4 (tr) 2018-03-21
EP2332577A1 (en) 2011-06-15
EP2848258B1 (en) 2017-12-13
ES2389110T3 (es) 2012-10-23
DK1940465T3 (da) 2012-10-22
JP2009513645A (ja) 2009-04-02
NO345140B1 (no) 2020-10-12
US9649377B2 (en) 2017-05-16
PH12020500559A1 (en) 2021-06-14
IL190545A (en) 2016-09-29
TW200803898A (en) 2008-01-16
JP2013166757A (ja) 2013-08-29
RU2008120625A (ru) 2010-01-20
IL258983B (en) 2020-10-29
KR20170038131A (ko) 2017-04-05
US20240083997A1 (en) 2024-03-14
PH12013501287A1 (en) 2016-02-01
AU2006306280B2 (en) 2010-06-17
LUC00078I2 (fr) 2018-08-14
NZ567222A (en) 2011-07-29
IL277406A (en) 2020-11-30
PH12013501287B1 (en) 2016-02-01
KR20080059598A (ko) 2008-06-30
LTC1940465I2 (lt) 2017-12-11
PL2848258T3 (pl) 2018-06-29
RU2012133522A (ru) 2014-02-20
IL245387A0 (en) 2016-06-30
EP3332807A2 (en) 2018-06-13
EP3332807B1 (en) 2023-02-22
US8409576B2 (en) 2013-04-02
IL245387B (en) 2019-09-26
KR20150013834A (ko) 2015-02-05
MA29919B1 (fr) 2008-11-03
CA2898369C (en) 2017-06-20
HK1121041A1 (en) 2009-04-17
NO20200810A1 (no) 2008-07-22
PT2848258T (pt) 2018-03-20
JOP20140120B1 (ar) 2021-08-17
CA2626214C (en) 2016-06-21
ES2662420T3 (es) 2018-04-06
TWI537003B (zh) 2016-06-11
JO2826B1 (en) 2014-09-15
EP1940465A2 (en) 2008-07-09
HK1204767A1 (en) 2015-12-04
EP3332807A3 (en) 2018-06-20
TW201302220A (zh) 2013-01-16
CY2018018I2 (el) 2018-12-12
CN101291693A (zh) 2008-10-22
CA2626214A1 (en) 2007-05-03
HUE036973T2 (hu) 2018-08-28
CA2963828A1 (en) 2007-05-03
LT2848258T (lt) 2018-02-26
CN101291693B (zh) 2012-10-03
HUS1800025I1 (hu) 2018-07-30
SI1940465T1 (sl) 2012-10-30
CY2013046I1 (el) 2015-11-04
ES2944067T3 (es) 2023-06-19
BRPI0617830B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CY1113378T1 (el) Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
DK1772465T3 (da) Syntetiske immunoglobulindomæner med modificerede bindingsegenskaber i områder af molekylet, der ikke er komplementaritetsbestemmende regioner
CY1122674T1 (el) Αντι-c5α συνδετiκα μορια με υψηλου βαθμου δραστiκοτητα αποκλεισμου
CY1122658T1 (el) Αντισωματα συνδεσης ανθρωπινου cgrp υποδοχεα
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
DK1912674T3 (da) Bispecifikt enkeltkæde FV-antistofmolekyle og fremgangsmåder til anvendelse deraf
CY1117241T1 (el) Αντισωματα anti-igf
MX2009012948A (es) Nuevas indicaciones para la terapia anti-il-1-beta.
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
CY1113087T1 (el) Ανθρωπινα αντισωματα εναντιον δελτα-παρομοιου προσδεματος 4
CY1111845T1 (el) Μορια δεσμευομενα me cd20
NL1021696A1 (nl) Destillaatbrandstofmengsels uit Fisher-Trposch-producten met verbeterde afdicht-opzwel-eigenschappen.
CY1118918T1 (el) Παραγοντες εξαλειψης κυτταρων β, οπως αντισωματα enanti-cd20 ή θραυσματα αυτων για την αντιμετωπιση συνδρομου χρονιας κοπωσης
Fuchs et al. How Large are Cooperative Effects in Hydrogen Bonded Molecular Chains?
TH126306A (th) การใช้งานแบบใหม่ของสารประกอบ il-1 เบตา
CY1117275T1 (el) Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους
CY1113928T1 (el) Αντισωματα αντι-μυοστατινης